202 related articles for article (PubMed ID: 12166500)
1. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis.
Chabot S; Yong FP; Le DM; Metz LM; Myles T; Yong VW
Mult Scler; 2002 Aug; 8(4):299-306. PubMed ID: 12166500
[TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
[TBL] [Abstract][Full Text] [Related]
3. Interaction of copolymer-1-activated T cells and microglia in retinal ganglion cell protection.
Qian S; Tang Y; Cheng L; Sun X; Tian J; Zhou C
Clin Exp Ophthalmol; 2013 Dec; 41(9):881-90. PubMed ID: 23566072
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
Aharoni R; Kayhan B; Eilam R; Sela M; Arnon R
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14157-62. PubMed ID: 14614135
[TBL] [Abstract][Full Text] [Related]
5. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.
Farina C; Weber MS; Meinl E; Wekerle H; Hohlfeld R
Lancet Neurol; 2005 Sep; 4(9):567-75. PubMed ID: 16109363
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.
Lalive PH; Neuhaus O; Benkhoucha M; Burger D; Hohlfeld R; Zamvil SS; Weber MS
CNS Drugs; 2011 May; 25(5):401-14. PubMed ID: 21476611
[TBL] [Abstract][Full Text] [Related]
7. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.
Kim HJ; Ifergan I; Antel JP; Seguin R; Duddy M; Lapierre Y; Jalili F; Bar-Or A
J Immunol; 2004 Jun; 172(11):7144-53. PubMed ID: 15153538
[TBL] [Abstract][Full Text] [Related]
8. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients.
Qin Y; Zhang DQ; Prat A; Pouly S; Antel J
J Neuroimmunol; 2000 Aug; 108(1-2):201-6. PubMed ID: 10900354
[TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis: modulation of apoptosis susceptibility by glatiramer acetate.
Aktas O; Ari N; Rieks M; Hoffmann V; Schimrigk S; Przuntek H; Pöhlau D
Acta Neurol Scand; 2001 Nov; 104(5):266-70. PubMed ID: 11696019
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
Dhib-Jalbut S
Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma.
Li Q; Milo R; Panitch H; Swoveland P; Bever CT
Eur J Pharmacol; 1998 Jan; 342(2-3):303-10. PubMed ID: 9548401
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Schrempf W; Ziemssen T
Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.
Chen M; Gran B; Costello K; Johnson K; Martin R; Dhib-Jalbut S
Mult Scler; 2001 Aug; 7(4):209-19. PubMed ID: 11548979
[TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
Ragheb S; Abramczyk S; Lisak D; Lisak R
Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate.
Arnon R; Aharoni R
J Neural Transm (Vienna); 2009 Nov; 116(11):1443-9. PubMed ID: 19669693
[TBL] [Abstract][Full Text] [Related]
16. Recent insights into the mechanism of action of glatiramer acetate.
Kala M; Miravalle A; Vollmer T
J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.
Arnon R; Aharoni R
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14593-8. PubMed ID: 15371592
[TBL] [Abstract][Full Text] [Related]
18. Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Poittevin M; Deroide N; Azibani F; Delcayre C; Giannesini C; Levy BI; Pocard M; Kubis N
J Neuroimmunol; 2013 Jan; 254(1-2):55-62. PubMed ID: 23026222
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory effects of glatiramer acetate on superantigen- and mitogen-induced T-cell stimulation in vitro.
Schmidt S; Balzer S; Nüllen C; Schmidt M; Pohl C; von Rücker A; Klockgether T
Mult Scler; 2002 Aug; 8(4):307-9. PubMed ID: 12166501
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.
Stüve O; Youssef S; Weber MS; Nessler S; von Büdingen HC; Hemmer B; Prod'homme T; Sobel RA; Steinman L; Zamvil SS
J Clin Invest; 2006 Apr; 116(4):1037-44. PubMed ID: 16543951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
